Patents Assigned to AEOVIAN PHARMACEUTICALS, INC.
  • mTORC modulators and uses thereof
    Patent number: 11702429
    Abstract: Novel rapamycin analogs and uses thereof are disclosed herein. The rapamycin analogs of the present disclosure show increased mTORC1 specificity and lowered mTORC2 specificity relative to rapamycin.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: July 18, 2023
    Assignee: AEOVIAN PHARMACEUTICALS, INC.
    Inventors: Stelios T. Tzannis, Ian J. Massey, Alexandre Froidbise, Guillaume Eppe
  • mTORC1 modulators and uses thereof
    Patent number: 11634432
    Abstract: The disclosure provides compounds and salts that show high selectivity and inhibitory activity for mTORC1 and uses thereof for the treatment of disease, such as Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 1, 2022
    Date of Patent: April 25, 2023
    Assignee: AEOVIAN PHARMACEUTICALS, INC.
    Inventor: John Kincaid
  • MTORC1 modulators and uses thereof
    Patent number: 11603377
    Abstract: The disclosure provides compounds and salts that show high selectivity and inhibitory activity for mTORC1 and uses thereof for the treatment of disease, such as Formula X: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: March 14, 2023
    Assignee: Aeovian Pharmaceuticals, Inc.
    Inventor: John Kincaid
  • mTORC modulators and uses thereof
    Patent number: 11230557
    Abstract: Novel rapamycin analogs and uses thereof are disclosed herein. The rapamycin analogs of the present disclosure show increased mTORC1 specificity and lowered mTORC2 specificity relative to rapamycin.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: January 25, 2022
    Assignee: Aeovian Pharmaceuticals, Inc.
    Inventors: Stelios T. Tzannis, Ian J. Massey, Alexandre Froidbise, Guillaume Eppe
  • mTORC modulators and uses thereof
    Patent number: 11021492
    Abstract: Novel rapamycin analogs and uses thereof are disclosed herein. The rapamycin analogs of the present disclosure show increased mTORC1 specificity and lowered mTORC2 specificity relative to rapamycin.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: June 1, 2021
    Assignee: AEOVIAN PHARMACEUTICALS, INC.
    Inventors: Stelios T. Tzannis, Ian J. Massey, Alexandre Froidbise, Guillaume Eppe